Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Institute Physician
RJ Corman Professor of Medicine
Harvard Medical School
Boston, MA
The ICARIA-MM and IKEMA-MM phase 3 trials have been pivotal in identifying Isa’s high efficacy and favorable tolerability profile as a notable therapy in the role of RRMM management. Recently, there have been additional updates illustrating the unique effects of Isa. This article focuses on these updates and how they may inform the role of Isa in the treatment of MM. Read More ›
